Valion Bio, Inc. Common Stock
Here’s whether Valion Bio, Inc. Common Stock (VBIO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-21.83% over 10 days); RSI 21 — oversold; 3-month momentum negative (-85.6%); rising volume on a downtrend (distribution, 2.85x avg). Currently 90.6% off its 52-week high. Score: -4/7.
VBIO is trading below its 200-day MA (—) — a key warning sign the longer-term trend is under pressure. An RSI of 21.3 has dropped into oversold territory, which has historically preceded short-term bounces. With ~4 months of trading history, the return since first available bar is -87.9%. The current 90.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.